shutterstock_1715090101_mark_van_scyoc

Mark Van Scyoc / Shutterstock.com

7 February 2022Big PharmaAlex Baldwin

PhRMA says EU, WTO, others are ‘weakening’ IP

Pharmaceutical industry consortium PhRMA has asked the Office of the US Trade Representative (USTR) to put the European Union, the World Trade Organization (WTO) and the UK on a watch list of trading partners that could “weaken” IP rights.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

PhRMA shames Brazil and Thailand over patent backlogs

6 November 2018 Pharmaceutical Research and Manufacturers of America has identified Brazil and Thailand as two of the worst countries for patent delays, in a submission made to a US government report.

BIO and PhRMA file petition supporting Illumina

7 March 2017 Two biotech associations have filed a petition asking the US Court of Appeals for the Federal Circuit to clarify rules on whether arguments can be brought at a district court if they have been brought at the US Patent and Trademark Office.

More on this story

PhRMA shames Brazil and Thailand over patent backlogs

6 November 2018 Pharmaceutical Research and Manufacturers of America has identified Brazil and Thailand as two of the worst countries for patent delays, in a submission made to a US government report.

BIO and PhRMA file petition supporting Illumina

7 March 2017 Two biotech associations have filed a petition asking the US Court of Appeals for the Federal Circuit to clarify rules on whether arguments can be brought at a district court if they have been brought at the US Patent and Trademark Office.

More on this story

PhRMA shames Brazil and Thailand over patent backlogs

6 November 2018 Pharmaceutical Research and Manufacturers of America has identified Brazil and Thailand as two of the worst countries for patent delays, in a submission made to a US government report.

BIO and PhRMA file petition supporting Illumina

7 March 2017 Two biotech associations have filed a petition asking the US Court of Appeals for the Federal Circuit to clarify rules on whether arguments can be brought at a district court if they have been brought at the US Patent and Trademark Office.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York